Literature DB >> 14763125

Strategies for treating cancers caused by multiple genome abnormalities: from concepts to cures?

Paul Workman1.   

Abstract

The epidemiology, genetics/genomics and molecular biology of cancer all point to the involvement of a large number of genes in the malignant progression of the vast majority of human cancers. Our current conceptual models of cancer are discussed here and are integrated with an assessment of the strategies required for treating and potentially curing human cancers driven by multiple genome abnormalities. There are settings in which excellent responses will be seen in cancers driven primarily by single genomic abnormalities, e.g., imatinib in chronic myeloid leukemia and gastrointestinal stromal tumors. Other multigenic cancers will require drug cocktails or single drugs acting on multiple downstream targets.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14763125

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  4 in total

Review 1.  Heat shock proteins as targets in oncology.

Authors:  Alejandra Giménez Ortiz; Joaquín Montalar Salcedo
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

Review 2.  Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective.

Authors:  Henry Rodriguez; Robert Rivers; Christopher Kinsinger; Mehdi Mesri; Tara Hiltke; Amir Rahbar; Emily Boja
Journal:  Proteomics Clin Appl       Date:  2010-11-22       Impact factor: 3.494

Review 3.  Restructuring proteomics through verification.

Authors:  Emily Boja; Robert Rivers; Christopher Kinsinger; Mehdi Mesri; Tara Hiltke; Amir Rahbar; Henry Rodriguez
Journal:  Biomark Med       Date:  2010-12       Impact factor: 2.851

Review 4.  Target therapy in metastatic pheochromocytoma: current perspectives and controversies.

Authors:  Amrallah A Mohammed; Ayman M El-Shentenawy; Mohamed A Sherisher; Hani M El-Khatib
Journal:  Oncol Rev       Date:  2014-09-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.